BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,876 | +0.2% | 547,328 | -0.4% | 0.00% | 0.0% |
| Q2 2023 | $3,870 | -34.0% | 549,739 | -21.8% | 0.00% | -33.3% |
| Q1 2023 | $5,864 | +5.4% | 703,173 | +45.1% | 0.00% | +50.0% |
| Q4 2022 | $5,562 | -99.9% | 484,492 | +17.7% | 0.00% | -66.7% |
| Q3 2022 | $5,184,000 | +464.7% | 411,516 | +373.6% | 0.01% | +500.0% |
| Q2 2022 | $918,000 | -53.8% | 86,883 | -29.0% | 0.00% | -50.0% |
| Q1 2022 | $1,989,000 | -67.1% | 122,327 | -72.0% | 0.00% | +100.0% |
| Q4 2021 | $6,054,000 | +433.9% | 437,064 | +453.8% | 0.00% | 0.0% |
| Q3 2021 | $1,134,000 | -38.5% | 78,916 | -32.3% | 0.00% | 0.0% |
| Q2 2021 | $1,843,000 | -36.8% | 116,569 | -59.3% | 0.00% | 0.0% |
| Q1 2021 | $2,916,000 | +299.5% | 286,693 | +192.5% | 0.00% | – |
| Q4 2020 | $730,000 | -40.3% | 98,030 | -72.5% | 0.00% | -100.0% |
| Q3 2020 | $1,222,000 | -51.2% | 356,105 | -32.3% | 0.00% | -50.0% |
| Q2 2020 | $2,504,000 | +9.0% | 525,811 | -54.2% | 0.00% | 0.0% |
| Q1 2020 | $2,298,000 | +212.7% | 1,148,846 | +439.4% | 0.00% | – |
| Q4 2019 | $735,000 | +8.4% | 213,004 | -9.8% | 0.00% | – |
| Q3 2019 | $678,000 | -69.0% | 236,206 | -59.1% | 0.00% | -100.0% |
| Q2 2019 | $2,187,000 | +23.6% | 576,837 | +165.4% | 0.00% | -50.0% |
| Q1 2019 | $1,769,000 | +142.0% | 217,325 | +139.8% | 0.00% | – |
| Q4 2018 | $731,000 | -0.7% | 90,634 | -6.0% | 0.00% | – |
| Q3 2018 | $736,000 | +222.8% | 96,448 | +143.0% | 0.00% | – |
| Q2 2018 | $228,000 | +2.2% | 39,698 | -15.3% | 0.00% | – |
| Q1 2018 | $223,000 | -47.2% | 46,874 | -45.4% | 0.00% | – |
| Q4 2017 | $422,000 | +13.1% | 85,873 | +20.4% | 0.00% | – |
| Q3 2017 | $373,000 | -78.5% | 71,295 | -77.1% | 0.00% | -100.0% |
| Q2 2017 | $1,732,000 | +261.6% | 311,616 | +446.8% | 0.00% | – |
| Q1 2017 | $479,000 | +3.2% | 56,987 | -22.1% | 0.00% | – |
| Q4 2016 | $464,000 | -20.7% | 73,164 | -44.7% | 0.00% | -100.0% |
| Q3 2016 | $585,000 | +828.6% | 132,314 | +491.4% | 0.00% | – |
| Q2 2016 | $63,000 | +6.8% | 22,373 | -25.1% | 0.00% | – |
| Q1 2016 | $59,000 | -90.9% | 29,868 | -53.9% | 0.00% | – |
| Q4 2015 | $648,000 | -49.5% | 64,737 | -44.5% | 0.00% | -100.0% |
| Q3 2015 | $1,282,000 | +9.2% | 116,617 | +38.9% | 0.00% | 0.0% |
| Q2 2015 | $1,174,000 | +192.8% | 83,984 | +88.8% | 0.00% | – |
| Q1 2015 | $401,000 | -73.5% | 44,482 | -64.8% | 0.00% | -100.0% |
| Q4 2014 | $1,515,000 | +32.1% | 126,291 | -1.0% | 0.00% | 0.0% |
| Q3 2014 | $1,147,000 | -3.9% | 127,508 | +28.1% | 0.00% | 0.0% |
| Q2 2014 | $1,193,000 | +76.2% | 99,555 | +47.0% | 0.00% | – |
| Q1 2014 | $677,000 | +70.5% | 67,740 | +19.5% | 0.00% | – |
| Q4 2013 | $397,000 | -64.4% | 56,708 | -64.4% | 0.00% | -100.0% |
| Q3 2013 | $1,115,000 | +306.9% | 159,290 | -10.0% | 0.00% | – |
| Q2 2013 | $274,000 | – | 176,986 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |